The COVID-19 pandemic has caused significant disruptions to ANCA vasculitis patient care, but these patients are not at higher risk for COVID-19 than the general population, despite receiving immunosuppressive therapy.
Researchers at Johns Hopkins identified “hot spots” in the Topo protein that are targeted by the immune system in scleroderma patients with different genetic backgrounds, which may help us understand why the immune system attacks healthy tissues in this autoimmune disease.
Hopkins researchers found that dermatomyositis patients with anti-Mi2 antibodies have more severe muscle disease but demonstrate improvement in muscle strength after treatment.
In this study, nearly half of patients that developed inflammatory arthritis after being treated with cancer immunotherapy still had active arthritis 6 months after their last immunotherapy treatment.
In this study, Hopkins investigators sought to determine the time to Lupus Low Disease Activity State attainment in a group of lupus patients and identify useful predictors of achieving this low disease state.
This study from the Johns Hopkins Scleroderma Center found that scleroderma patients with multiple autoimmune responses may be protected from the development of cancer.
